Vaccine

BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023

MAINZ, Germany, March 13, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial…

1 year ago

Cytovance Biologics and Phenotypeca Collaborate to Enhance Saccharomyces cerevisiae Strain Development for Microbial Biomanufacturing

OKLAHOMA CITY, March 11, 2023 (GLOBE NEWSWIRE) -- Cytovance Biologics, Inc. (Cytovance Biologics), a biopharmaceutical contract development and manufacturing organization…

1 year ago

Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights

CINCINNATI, March 09, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today…

1 year ago

Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis

Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks…

1 year ago

OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate

MDX-2201 leverages ModeX’s innovative biologics platform to target multiple Epstein-Barr virus (EBV) proteinsEBV is the leading cause of infectious mononucleosis…

1 year ago

Maravai LifeSciences Announces March 2023 Investor Conference Schedule

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents…

1 year ago

Inovalon Announces Converged Provider Enablement

A SaaS Solution that Aligns Disparate Quality, Risk, and Custom Value-Based Initiatives Across Multiple Provider Points of CareBOWIE, Md., March…

1 year ago

SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal

Safety and Immunogenicity Examined in Phase 1 Trial of GPS plus Anti–PD-1 Nivolumab in Patients with WT1-Expressing Relapsed Ovarian Cancer…

1 year ago

Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

Dosing of all patients was completed at the end of February  No Serious Adverse Events (SAE’s) have been reported  Phase 1 clinical…

1 year ago

Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference

MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines…

1 year ago